SITC 2024 Poster 508

A Novel In Vitro Assay to Evaluate the Potency of Anti-PD-1 and Anti-PD-L1 Drugs in NSCLC

Xuefei Yan, Shiqi Guo, Jiawei Meng, Meng Zhang, Haijuan Yu, Jie Lin, Saskia De Man, Ludovic Bourre, Jun Zhou

Explore Crown Bioscience’s innovative in vitro assay, designed to evaluate the potency of anti-PD-1 and anti-PD-L1 drugs in non-small cell lung cancer (NSCLC). By leveraging advanced co-culture systems with patient-derived cells, this assay provides a robust platform for early-stage immunotherapy testing, facilitating a deeper understanding of immune checkpoint inhibitor efficacy. Discover how this assay can contribute to accelerating the drug development process for immuno-oncology therapeutics.

Download this Poster to Discover:

• Assay Design and Purpose: Gain insights into how this assay was developed to assess the potency of PD-1 and PD-L1 blocking drugs in NSCLC, using PBMCs and immune co-culture techniques.
  
  
• Experimental Methods: Review the co-culture setup with activated immune cells and tumor cells, offering a high-throughput testing approach for checkpoint inhibitor efficacy.
  
  
• Checkpoint Inhibition Analysis: Explore detailed data on PD-1 and PD-L1 expression on various cell types, measured using advanced flow cytometry and luminescence techniques.
  
  
• Key Findings on T Cell Activation and Cytotoxicity: Understand how T cell activation and tumor cell killing were measured over time, highlighting the immune response to checkpoint inhibitors.
  
  
• Results on Drug Potency: Discover comparative findings for different immune cell donors and their responses to anti-PD-1/PD-L1 drugs, with insights into the assay’s reproducibility and predictive value.
  
  
• Clinical Relevance: Learn about the implications of this assay in early drug screening and how it can support the development of new molecules targeting PD-1/PD-L1 pathways in cancer immunotherapy.

Download the Poster Now!